Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogs
MIRA•Formulation and manufacturing work continues
Formulation, manufacturing, and CMC work continued to prepare for GLP toxicology and subsequent clinical development.
Preclinical candidates move toward IND-enabling work
Mira Pharmaceuticals moved two preclinical oral candidates, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders, toward IND-enabling studies.
Exploratory repeat-dose studies completed in rats and dogs
No clinical results were presented; exploratory 7-day repeat-dose safety studies in rats and dogs completed dosing and necropsy, with analyses still underway.
Early readouts are intended to support tolerability assessment and dose selection for upcoming GLP IND-enabling toxicology, not to establish efficacy.
